PF-08049820 for Eczema
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment, PF-08049820, to determine its safety and effectiveness for people with atopic dermatitis (eczema), a condition causing intense itching and rashes. Participants will take the treatment or a placebo (a harmless pill with no active medicine) for 12 weeks. The goal is to compare the health outcomes and skin conditions of those taking the real treatment with those taking the placebo. The trial seeks individuals who have had moderate to severe eczema for at least six months and lack a suitable prescribed medicine for their condition. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, it mentions that participants should not have a suitable prescribed medicine for eczema, which might imply that you should not be on effective eczema medication.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that PF-08049820 is being tested for safety in treating eczema. In studies with healthy adults, the treatment was generally well-tolerated, with most participants experiencing no serious issues. Some did report mild side effects, but these were not severe. As this study remains in the early stages, more information is needed to fully assess the safety of PF-08049820 for individuals with eczema. However, reaching this phase of testing suggests some confidence in its safety thus far.12345
Why do researchers think this study treatment might be promising for eczema?
Unlike the standard treatments for eczema, which often include topical steroids, moisturizers, and immunosuppressants, PF-08049820 introduces a novel approach by being taken orally. This treatment is unique because it targets specific pathways involved in the inflammatory process of eczema, potentially reducing side effects associated with topical or systemic treatments. Researchers are excited about PF-08049820 because it offers the possibility of a more convenient and potentially more effective treatment for eczema without the common drawbacks of current therapies.
What evidence suggests that PF-08049820 might be an effective treatment for eczema?
Research shows that PF-08049820, which participants in this trial may receive, may help treat atopic dermatitis, also known as eczema. Early results suggest this medication can greatly improve skin condition by reducing severe itching and rashes. In past studies, patients felt noticeable relief and had healthier skin. The treatment outperformed a placebo, making it a potential option for those with moderate to severe eczema. While more research is needed, these findings offer hope for people dealing with eczema.12356
Who Is on the Research Team?
Pfizer CT.gov Call Center
Principal Investigator
Pfizer
Are You a Good Fit for This Trial?
Adults over 18 with moderate to severe atopic dermatitis (eczema) for at least 6 months, who haven't found an effective prescribed treatment. Participants should have a significant area of their body affected and experience intense itching. They must weigh over 100 lbs and have a BMI between 17.5 to 40 kg/m2.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either PF-08049820 or placebo as tablets by mouth daily for 12 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- PF-08049820
Find a Clinic Near You
Who Is Running the Clinical Trial?
Pfizer
Lead Sponsor
Albert Bourla
Pfizer
Chief Executive Officer since 2019
PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki
Patrizia Cavazzoni
Pfizer
Chief Medical Officer
MD from McGill University